Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): I. As2O3 exerts dose-dependent dual effects on APL cells.
about
PML nuclear bodiesRegulation of p53 activity in nuclear bodies by a specific PML isoformThe growth suppressor PML represses transcription by functionally and physically interacting with histone deacetylasesArsenic trioxide is a potent inhibitor of the interaction of SMRT corepressor with Its transcription factor partners, including the PML-retinoic acid receptor alpha oncoprotein found in human acute promyelocytic leukemiaFrom an old remedy to a magic bullet: molecular mechanisms underlying the therapeutic effects of arsenic in fighting leukemiaAuranofin induces apoptosis and when combined with retinoic acid enhances differentiation of acute promyelocytic leukaemia cells in vitroRetinoic acid and arsenic for treating acute promyelocytic leukemiaThe molecular mechanisms of arsenic-induced cell transformation and apoptosis.Tetrandrine, a Chinese plant-derived alkaloid, is a potential candidate for cancer chemotherapyAcute Promyelocytic Leukemia (APL): Comparison Between Children and AdultsPIC-1/SUMO-1-modified PML-retinoic acid receptor alpha mediates arsenic trioxide-induced apoptosis in acute promyelocytic leukemiaArsenic trioxide sensitivity is associated with low level of glutathione in cancer cellsRetinoic acid (RA) and As2O3 treatment in transgenic models of acute promyelocytic leukemia (APL) unravel the distinct nature of the leukemogenic process induced by the PML-RARalpha and PLZF-RARalpha oncoproteinsArsenic inhibition of telomerase transcription leads to genetic instabilityArsenic-induced PML targeting onto nuclear bodies: implications for the treatment of acute promyelocytic leukemiaLow-Concentration Arsenic Trioxide Inhibits Skeletal Myoblast Cell Proliferation via a Reactive Oxygen Species-Independent PathwayArsenic exposure predicts bladder cancer survival in a US populationArsenic induces functional re-expression of estrogen receptor α by demethylation of DNA in estrogen receptor-negative human breast cancerArsenic trioxide induces apoptosis in human platelets via C-Jun NH2-terminal kinase activationToxicology of chemically modified graphene-based materials for medical application.Retinoic acid and arsenic synergize to eradicate leukemic cells in a mouse model of acute promyelocytic leukemiaIn vivo activation of cAMP signaling induces growth arrest and differentiation in acute promyelocytic leukemia.BCL-2 cooperates with promyelocytic leukemia retinoic acid receptor alpha chimeric protein (PMLRARalpha) to block neutrophil differentiation and initiate acute leukemia.Differentiation therapy of leukemia: 3 decades of development.The absence of interleukin-6 enhanced arsenite-induced renal injury by promoting autophagy of tubular epithelial cells with aberrant extracellular signal-regulated kinase activation.Ascorbic Acid Potentiation of Arsenic Trioxide Anticancer Activity Against Acute Promyelocytic Leukemia.Arsenic trioxide inhibits tumor-induced myeloid-derived suppressor cells and enhances T-cell activity.Curing all patients with acute promyelocytic leukemia: are we there yet?Arsenic trioxide cooperates with all trans retinoic acid to enhance mitogen-activated protein kinase activation and differentiation in PML-RARalpha negative human myeloblastic leukemia cells.Quantitative proteomic analysis reveals the perturbation of multiple cellular pathways in HL-60 cells induced by arsenite treatment.Cooperative antitumor effects of vitamin D3 derivatives and rosemary preparations in a mouse model of myeloid leukemiaArsenic trioxide induces oxidative stress, DNA damage, and mitochondrial pathway of apoptosis in human leukemia (HL-60) cells.Effects of arsenic on osteoblast differentiation in vitro and on bone mineral density and microstructure in rats.Modulation of p53, c-fos, RARE, cyclin A, and cyclin D1 expression in human leukemia (HL-60) cells exposed to arsenic trioxideArsenic trioxide inhibits EBV reactivation and promotes cell death in EBV-positive lymphoma cells.Interactions of herpes simplex virus type 1 with ND10 and recruitment of PML to replication compartments.PTEN is a negative regulator of mitotic checkpoint complex during the cell cyclePhase II study of arsenic trioxide and ascorbic acid for relapsed or refractory lymphoid malignancies: a Wisconsin Oncology Network studyArsenic trioxide downregulates specificity protein (Sp) transcription factors and inhibits bladder cancer cell and tumor growthArsenic trioxide inhibits nuclear receptor function via SEK1/JNK-mediated RXRalpha phosphorylation.
P2860
Q22065791-B433B4F1-01C7-4905-9F0F-F74283BA33F6Q24290520-F3C3419F-BBAE-4F95-AC95-B922ACC63411Q24290948-6DD48FF4-8611-414E-9BEA-F5C50D8FCF0EQ24548302-C2E9D652-1217-4BCE-8C39-4C2AF7CB3C1DQ24605527-C24AC97D-2EAA-4706-9F3B-EEC3C9D8E32EQ24671800-FB549CD0-709D-4934-8B39-3693838EDC93Q24809165-59431C15-0611-41CC-BA86-59F343CC1CD4Q24812452-261F3E33-D3E1-49B3-9BA3-A490F19631B3Q26749391-AA385021-E522-4E82-852B-97F91E231C49Q27009433-4291D996-3B9D-40FB-84E0-FAA3110679E6Q28343393-95988B62-BFA3-4937-9FBC-EC7443EC3A43Q28343686-1E5C3401-6FEB-485E-9570-0D403C6FCE74Q28344657-7EF37D3F-AA75-4DBE-AB49-85977D8F25D1Q28364496-045053A5-2A44-477E-AA08-A74A6AF0A5D4Q28379542-59873F02-8BA3-4901-BA2B-9B094764337EQ28388442-47DCE890-85FE-45FC-A938-F40B178AA752Q28397390-D6C181F9-618F-4EC1-B02C-80092BFD84E8Q28482827-C3484E22-B991-48DB-9083-E8D74913BA34Q28539034-5F106BA5-6C87-46F1-A2D6-EC3776197804Q30427860-D6D39D34-6036-4F90-847B-5AD4405A7DF8Q33178068-7BB3E7FB-F7AA-42BD-B93A-6458E1A90674Q33185196-8E060C22-B1CA-4EE4-8D50-20398ABEB4B2Q33335885-150F4635-563D-4B1B-9187-9BC432FD76D0Q33409795-810EE2E7-59E2-4E83-8CD7-068F8F9B8D00Q33556218-3771EC58-4C4B-4985-9341-0DBEDA4BF68FQ33588205-520DA6FF-3951-460D-AA3E-550E5C5957BCQ33598739-009D5046-7CC9-413A-8145-63EFF7247DE6Q33613426-2ED1ED73-6FDB-436C-89FC-A74E3A112141Q33628050-E1E23A6F-ED60-4BDF-B413-7C07EBF52268Q33640702-C8AD224A-8D9A-4171-B646-C50914C974FBQ33668436-61337311-954C-4A38-AF59-84D85ECCACFAQ33726127-F0AC17BE-CE9D-474E-90BB-DFDF9CB4EE63Q33730279-2D2C1404-1530-490A-B562-DEE46567BAFAQ33791820-3670C3ED-27DB-4D82-A892-EBAC81A6776EQ33823359-6D8054A8-1A89-45A8-8187-DE37359E0C38Q33850767-8C604A09-A4C4-4740-A1E6-43FC63BDDFF7Q33857310-47337556-72F2-4809-B9E1-95EF38FF4381Q33962155-249F1BD4-B2E6-4B09-A46A-62D7BDB3533AQ33976179-3FE19C24-0BE6-4DBA-AF49-553993BEB96DQ34014502-A9293345-F6F8-4617-ABE9-DD327E2ABFF7
P2860
Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): I. As2O3 exerts dose-dependent dual effects on APL cells.
description
1997 nî lūn-bûn
@nan
1997 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
1997 թվականի մայիսին հրատարակված գիտական հոդված
@hy
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
name
Use of arsenic trioxide (As2O3 ...... ent dual effects on APL cells.
@ast
Use of arsenic trioxide (As2O3 ...... ent dual effects on APL cells.
@en
type
label
Use of arsenic trioxide (As2O3 ...... ent dual effects on APL cells.
@ast
Use of arsenic trioxide (As2O3 ...... ent dual effects on APL cells.
@en
prefLabel
Use of arsenic trioxide (As2O3 ...... ent dual effects on APL cells.
@ast
Use of arsenic trioxide (As2O3 ...... ent dual effects on APL cells.
@en
P2093
P1433
P1476
Use of arsenic trioxide (As2O3 ...... ent dual effects on APL cells.
@en
P2093
K Kitamura
P304
P407
P577
1997-05-01T00:00:00Z